Background illustration for clinical trials search

Paid Clinical Trials San Francisco

Discover 2,226 paid clinical trials in San Francisco, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 2,226

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for

Castration-Sensitive Prostate Carcinoma,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male

Age: 18+

Code: NCT06931340

Phase3, Recruiting

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

for

Severe Aortic Stenosis, Valve-in-valve Procedures

Location: San Francisco CA, Wichita KS, Minneapolis MN,

Sponsor: Anteris Technologies Ltd.

Sex: All

Age: 18+

Code: NCT07194265

Recruiting

E-Mindfulness Approaches for Living After Breast Cancer

for

Breast Cancer, Depression

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: NRG Oncology

Sex: All

Age: 18 - 50

Code: NCT06748222

Phase3, Recruiting

Vancomycin Reduction Practices (VRP) in the NICU

for

Antibiotic Stewardship, Neonatal Sepsis, Late-Onset, Vancomycin

Location: San Francisco CA, Oakland CA, San Leandro CA,

Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 18+

Code: NCT06772675

Recruiting

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

for

Metastatic Salivary Gland Carcinoma,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05408845

Phase2, Recruiting

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

for

Prostate Cancer

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06235697

Phase3, Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: San Francisco CA, Berkeley CA, San Mateo CA, Vallejo CA,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT06031688

Phase2, Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for

Ovarian Carcinoma

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: NRG Oncology

Sex: Female

Age: 35 - 50

Code: NCT04251052

Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: NRG Oncology

Sex: Male

Age: 18+

Code: NCT05946213

Phase3, Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for

Metastatic Nasopharyngeal Carcinoma,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06029270

Phase2, Recruiting

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

for

Mitral Valve Regurgitation

Location: San Francisco CA, Stanford CA, Mountain View CA,

Sponsor: Medtronic Cardiovascular

Sex: All

Age: 18+

Code: NCT03242642

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05987241

Phase2, Phase3, Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 5 - 60

Code: NCT05675410

Phase3, Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for

Castration Levels of Testosterone,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT03678025

Phase3, Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors

Location: San Francisco CA, Oakland CA, Berkeley CA,

Sponsor: American Society of Clinical Oncology

Sex: All

Age: 12+

Code: NCT02693535

Phase2, Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: San Francisco CA, South San Francisco CA, Oakland CA,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642572

Phase2, Recruiting

Paid Clinical Trials San Francisco

Filter results

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

E-Mindfulness Approaches for Living After Breast Cancer

Vancomycin Reduction Practices (VRP) in the NICU

Interested in new trials?

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)